RXRX (Recursion Pharmaceuticals) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RXRX Recursion Pharmaceuticals Inc RXRX
79 GF Score
Price $3.16
GF Value $3.12
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Recursion Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

RXRX vs INVA, TSHA, MLTX: Short Interest Comparison

For the Biotechnology subindustry, Recursion Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Recursion Pharmaceuticals Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Recursion Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Recursion Pharmaceuticals's Short Interest falls into.


RXRX
79GF Score
Recursion Pharmaceuticals Inc RXRX
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Recursion Pharmaceuticals (RXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be overvalued. The current stock price of $3.16 is trading 1.3% above its estimated GF Value™ of $3.12. GuruFocus considers Recursion Pharmaceuticals to be Fairly Valued.

Key valuation signals for RXRX:

  • Short Interest:
  • GF Value™: $3.12 vs. price of $3.16 (1.3% above fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Recursion Pharmaceuticals Business Description

Other Exchanges RXRX:Mexico
Address 41 South Rio Grande Street, Salt Lake City, UT, USA, 84101
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
79GF Score

Get the complete analysis for RXRX

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.16
Price
$3.12
GF Value